Smallpox: The basics

Dermatologic Clinics

Volumn 22, Issue 3, 2004, Pages 263-274

  Slifka, Mark K ^a   Hanifin, Jon M ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CIDOFOVIR; PROBENECID; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA ANTIBODY; VIRUS VACCINE;

ALASTRIM; ANTIBODY PRODUCTION; CELLULAR IMMUNITY; CLINICAL FEATURE; COWPOX; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ERADICATION THERAPY; GENETIC ENGINEERING; HUMAN; IMMUNIZATION; NEPHROTOXICITY; NONHUMAN; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SMALLPOX; SMALLPOX VIRUS; UNITED STATES; USSR; VACCINIA; VIRULENCE;

BIOLOGICAL WARFARE; BIOTERRORISM; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; MALE; RISK ASSESSMENT; SMALLPOX; SMALLPOX VACCINE; SURVIVAL RATE; UNITED STATES; VACCINATION; VARIOLA VIRUS; WORLD HEALTH;

EID: 2942669895     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2004.03.002     Document Type: Review

References (76)

1. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. In: The pathogenesis, immunology, and pathology of smallpox and vaccinia. Geneva (Switzerland): World Health Organization; 1988.
2. Smith GL, McFadden G. Science and society: smallpox: anything to declare? Nat Rev Immunol 2002;521-7.
3. Finkel E. Australia. Engineered mouse virus spurs bioweapon fears. Science 2001;291:585.
4. Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 2001;75:1205-10.
5. Sharma DP, Ramsay AJ, Maguire DJ, Rolph MS, Ramshaw IA. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol 1996;70:7103-7.
6. Bembridge GP, Lopez JA, Cook R, Melero JA, Taylor G. Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon. J Virol 1998;72:4080-7.
7. Aung S, Graham BS. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity vivo. J Immunol 2000;164:3487-93.
8. Rolph MS, Ramshaw IA. Interleukin-4-mediated downregulation of cytotoxic T lymphocyte activity associated with reduced proliferation of antigen-specific CD8+T-cells. Microbes Infect 2003;5:923-32.
9. Smith SA, Kotwal GJ. Immune response to poxvirus infections in various animals. Crit Rev Microbiol 2002;28:149-85.
10. Mack T. A different view of smallpox and vaccination. N Engl J Med 2003;348:460-3.
11. Shchelkunov SN, Massung RF, Esposito JJ. Comparison of the genome DNA sequences of Bangladesh-1975 and India-1967 variola viruses. Virus Res 1995;36:107-18.
12. Shchelkunov SN, Totmenin AV, Loparev VN, Safronov PF, Gutorov VV, Chizhikov VE, et al. Alastrim smallpox variola minor virus genome DNA sequences. Virology 2000;266:361-86.
13. Poxvirus Bioinformatics Resource Center. Available at: http://www.poxvirus.org. Accessed March 2004.
14. Agromayor M, Ortiz P, Lopez-Estebaranz JL, Gonzalez-Nicolas J, Eateban M, Martin-Gallardo A. Molecular epidemiology of molluscum contagiosum virus and analysis of the host-serum antibody response in Spanish HIV-negative patients. J Med Virol 2002;66:151-8.
15. Zinkernagel RM, Althage A. Antiviral protection by virus-immune cytotoxic T-cells: infected target cells are lysed before infectious virus progeny is assembled. J Exp Med 1977;145:644-51.
16. Perrin LH, Zinkernagel RM, Oldstone MB. Immune response in humans after vaccination with vaccinia virus: generation of a virus-pecific cytotoxic activity by human peripheral lymphocytes. J Exp Med 1977;146:949-69.
17. Perrin LH, Reynolds D, Zinkernagel R, Oldstone MB. Generation of virus-specific cytolytic activity in human peripheral lymphocytes after vaccination with vaccination with vaccinia virus and measles virus. Med Microbiol Immunol (Berl) 1978;166:71-9.
18. Littaua RA, Takeda A, Cruz J, Ennis FA. Vaccinia virus-specific human CD4+ cytotoxic T-lymphocyte clones. J Virol 1992;66:2274-80.
19. Demkowicz Jr WE, Ennis FA. Vaccinia virus-specific CD8+ cytotoxic T lymphocytes in humans. J Virol 1993;67:1538-44.
20. Demkowicz WEJ, Littaua RA, Wang J, Ennris FA. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J Virol 1996;70:2627-31.
21. Ennis FA, Cruz J, Demkowicz Jr WE, Rothman AL, McClain DJ. Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T-cells after smallpox vaccination. J Infect Dis 2002;185:1657-9.
22. Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med 2003;1125-30.
23. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003;171:4969-73.
24. Terajima M, Cruz J, Raines G, Kilpatrick ED, Kennedy JS, Rothman AL, et al. Quantitation of CD8+ T-cell responses to newly identified HLA-A*0201-restricted T-cell epitopes conserved among vaccinia and variola (smallpox) viruses. J Exp Med 2003;197:1927-32.
25. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003;1131-7.
26. Henderson DA. The looming threat of bioterrorism. Science 1999;283:1279-82.
27. Meltzer MI, Damon I, LeDuc JW, Millar JD. Modeling potential responses to smallpox as a bioterrorist weapon. Emerg Infect Dis 2001;7:959-69.
28. Gani R, Leach S. Transmission potential of smallpox in contemporary populations. Nature 2001;414:748-51.
29. Kaplan EH, Craft DL, Wein LM. Emergency response to a smallpox attack: the case for mass vaccination. Proc Nat1 Acad Sci U S A 2002;99:10935-40.
30. O'Toole T, Mair M, Inglesby TV. Shining light on "Dark Winter". Clin Infect Dis 2002;34:972-83.
31. Mack TM, Noble Jr J, Thomas DB. A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg 1972;21:214-8.
32. Sarkar JK, Mitra AC, Mukherjee MK. The minimum protective level of antibodies in smallpox. Bull World Health Organ 1975;52:307-11.
33. Downie AW, McCarthy K. The antibody response in man following infection with viruses of the pox group. III. Antibody response in smallpox. J Hyg 1958;56:479-87.
34. Gayton W. The value of vaccination as shown by an analysis of 10,403 cases of smallpox. London: Gillett & Henty; 1885.
35. Hanna W. Studies in smallpox and vaccination. New York: William Wood and Company; 1913.
36. Hanna W, Baxby D. Studies in smallpox and vaccination. 1913. Rev Med Virol 2002;12:201-9.
37. Centers for Disease Control and Prevention. Smallpox. MMWR 1963;12:172, 174-176, 183, 188, 191, 220, 236.
38. Mack TM. Smallpox in Europe, 1950-1971. J Infect Dis 1972;125:161-9.
39. Eichner M. Analysis of historical data suggest longlasting protective effects of smallpox vaccination. Am J Epidemiol 2003;158:717-23.
40. McCarthy K, Downie AW. The antibody response in man following infection with viruses of the pox group. II. Antibody response following vaccination. J Hyg 1958;56:466-78.
41. el-Ad B, Roth Y, Winder A, Tochner Z, Lublin-Tennenbaum T, Katz E, et al. The persistence of neutralizing antibodies after revaccination against smallpox. J Infect Dis 1990;161:446-8.
42. Stienlauf S, Shoresh M, Solomon A, Lublin-Tennenbaum T, Atsmon Y, Meirovich Y, et al. Kinetics of formation of neutralizing antibodies against vaccinia virus following re-vaccination. Vaccine 1999;17:201-4.
43. Frey SE, Newman FK, Yan L, Belshe RB. Response to smallpox vaccine in persons immunized in the distant past. JAMA 2003;289:3295-9.
44. Bras G. Observations on the formation of smallpox scars. Arch Pathol 1952;54:149-56.
45. Rook A, Wilkinson DS, Ebling FJG. Textbook of dermatology. Philadelphia: F.A. Davis; 1968.
46. Engler RJM, Kenner J, Leung DYM. Smallpox vaccination: risk considerations for patients with atopic dermatitis. J Allergy Clin Immunol 2002;110:357-65.
47. Bras G. The morbid anatomy of smallpox. Doc Med Geogr Trop 1952;4:303-51.
48. Sarkar JK, Mitra AC, Mukherjee MK, De SK. Virus excretion in smallpox. 2. Excretion in the throats of houshold contacts. Bull World Health Organ 1973;48:1523-7.
49. Roberts JA. Histopathogenesis of mousepox. I. Respiratory infection. Br J Exp Pathol 1962;43:451-61.
50. Bremen JG, Henderson DA. Diagnosis and management of smallpox. N Engl J Med 2002;346:1300-8.
51. Rao AR. Smallpox. Bombay (India): Kothari Book Depot; 1972.
52. Dixon CW. Smallpox. London: J. & A. Churchill; 1962.
53. Kempe CH, Dekking F, St. Vincent L, Rao AR, Downie AW. Conjunctivitis and subclinical infection in smallpox. J Hyg (Lond) 1969;67:631-6.
54. Dworetzky M. Smallpox, October 1945 [letter]. N Engl J Med 2002;346:1329.
55. Fulginiti VA. In: Fitzpatrick's dermatology in general medicine. 6th edition. McGraw Hill; 2003. p. 2103-6
56. de Korte WE. Amaas, or kaffir milk-pox. Lancet 1904;1:1273-6.
57. de Jong M. The alastrim epidemic in The Hague, 1953- 1954. Doc Med Geogr Trop 1956;8:207-35.
58. Marsden JP. A critical review of the clinical features of 13,686 cases of smallpox (variola minor). London: London County Council (report no. 3209); 1936. [Reprinted as: Variola minor. A personal analysis of 13,686 cases. Bull Hyg (Lond) 1948;23:735- 46].
59. Marsden JP. A critical review of the clinical features of 13,686 cases of smallpox (variola minor). London: London County Council (report no. 3209); 1936. [Reprinted as: Variola minor. A personal analysis of 13,686 cases. Bull Hyg (Lond) 1948;23:735-46].
60. Reed KD, Melski JW, Graham MB, Regenery RL, Sotir MJ, Wegner MV, et al. The initial detection of human monkeypox in the Western Hemisphere: association with infected prairie dogs. N Engl J Med 2004;350:342-50.
61. Hawranek T, Tritscher M, Muss WH, Jecel J, Nowotny N, Kolodziejek J, et al. Feline orthopoxvitus infection transmitted from cat to human. J Am Acad Dermatol 2003;49:513-8.
62. Centers for Disease Control and Prevention. Smallpox questions and answers: the disease and the vaccine. Available at: http://www.bt.cdc.gov/agent/ smallpox/overview/faq.asp. Accessed March 2004.
63. Massoudi MS, Barker L, Schwartz B. Effectiveness of postexposure vaccination for the prevention of smallpox: results of a delphi analysis. J Infect Dis 2003;188:973-6.
64. Mortimer PP. Can postexposure vaccination against smallpox succeed? Clin Infect Dis 2003;36:622-9.
65. Couzi G, Kircher JP. Immunotherapie de la Variole. Bulletin de l'Institut d'hygiene du Maroc 1941;1:59-68.
66. Marennikova SS. The use of hyperimmune antivaccinia gamma-globulin for the prevention and treatment of smallpox. Bull World Health Organ 1962;27:325- 30.
67. Kempe CH, Berge TO, England B. Hyperimmune vaccinial gamma globulin. Pediatrics 1956;18:177-88.
68. Pierce ER, Melville FS, Downie AW, Duckworth MJ. Antivaccinial gamma-globulin in smallpox prophylaxis. Lancet 1958;2:635-8.
69. Kempe CH, Bowles C, Meiklejohn G, Berge TO, St. Vincent L, Babu BVS, et al. The use of vaccinia hyperimmune gammaglobulin in the prophylaxis of smallpox. Bull World Health Organ 1961;25:41-8.
70. Patel TB, Naidu BPB. Smallpox and sulphonamide. Indian Med Gaz 1940;75:730-2.
71. Whitton JL, Slifka MK, Liu F, Nussbaum AK, Whitmire JK. The regulation and maturation of antiviral immune responses. Adv Vir Res, in press.
72. Smallpox Adverse Event Workshop. Vaccinia immune globulin and cidofovir. CDC. January 22-23, 2003.
73. De Clercq E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol Sci 2002;23:456-8.
74. Bray M, Martinez M, Smee DF, Kefauver D, Thompson E, Huggins JW. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis 2000;181:10-9.
75. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001;7:388-94.
76. Hatakeyama N, Suzuki N, Kudoh T, Hori T, Mizue N, Tsutsumi H. Successful cidofovir treatment of adenovirus-associated hemorrhagic cystitis and renal dysfunction after allogenic bone marrow transplant. Pediatr Infect Dis J 2003;22:928-9.